University of California San Diego Medical Center, La Jolla, California, USA.
Yale School of Medicine, New Haven, Connecticut, USA.
Clin Pharmacol Ther. 2018 Aug;104(2):301-310. doi: 10.1002/cpt.1024. Epub 2018 Feb 13.
Atrial fibrillation (AF) is a leading cause of stroke. Oral anticoagulant (OAC) therapy can significantly reduce the risk of stroke in patients with AF, but underuse of OACs for stroke prevention continues to be a serious clinical problem, with significant deleterious impact on outcomes. We review the studies demonstrating OAC underutilization and evaluating strategies for promoting the increased use of OAC therapy for stroke prevention in nonvalvular AF (NVAF) patients, including in special patient populations.
心房颤动（AF）是中风的主要原因。口服抗凝剂（OAC）治疗可显著降低 AF 患者中风的风险，但 OAC 预防中风的使用率仍然很低，这对结果产生了重大的不利影响。我们回顾了证明 OAC 使用率不足的研究，并评估了促进非瓣膜性心房颤动（NVAF）患者 OAC 治疗用于中风预防的增加使用的策略，包括特殊患者人群。
